Item 1.01 Entry Into a Definitive Material Definitive Agreement.
On July 7, 2016, Emerald Medical Applications Corp., OTCQB: MRLA (the "Registrant") announced that it was awarded first prize over 3,500 other competing tech companies in the Publicis Groupe 90 initiative at the inaugural edition of Viva Technology Paris. The Registrant was awarded first prize for its DermaCompare™ skin cancer screening application, which award included 500,000 Euro.
On February 24, 2017, the Registrant accepted the signed Reg S Subscription Agreement from Publicis 90 together with its wire transfer for US$526,213 in consideration for the issuance to Publicis 90 of 1,315,563 restricted shares of the Registrant's common stock (the "Shares") at a subscription price of $0.40 per Share.
Item 3.02 Unregistered Shares of Equity Securities.
Pursuant to the terms of the Reg S Subscription Agreement, the Registrant issued a total of 1,315,563 restricted Shares to IRIS Capital Management ("IRIS"), a venture capital arm of the Publicis Groupe, Paris France. The issuance of the Shares was made in reliance upon the exemptions provided in Section 4(2) of the Securities Act of 1933, as amended (the "Act") and Regulation S promulgated by the SEC under the Act.
Item 8.01. Other Events.
The Registrant, in its press release attached hereto as Exhibit 99.1 to this 8-K, announced it has received Reference is made to the full text of the press release filed as Exhibit 99.1 herewith.
Item 9.01 Financial Statements and Exhibits.
(a) The following documents are filed as exhibits to this report on Form 8-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.
Exhibit No.
Description
99.1 Press Release dated February 27, 2017, filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ Yair Fudim
Chairman
Yair Fudim
Date: February 27, 2017
Exhibit 99.1
IRIS Capital Management Purchases Approximately 6% of the common shares of Emerald Medical Applications at $.40 per Share
Purchase resulted from Emerald Medical Applications winning The Grand Prize at Publicis Groupe "Publicis 90" Initiative
My post are for entertainment only ...I do not suggest or tell people when to buy or sell..... GLTA STACKER
